AXIM® Biotech Receives Positive PK Data Results for CanChew …

NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in cannabinoid research and development, received positive pharmacokinetic (PK) data results on its CanChew Plus® CBD Gum, and gears up for clinical trial on alleviating the symptom of irritable bowel syndrome (IBS).

The single dose study on 10 mg of cannabidiol (CBD) and 30 mg of CBD determined the concentration of CBD in the blood after chewing one CanChew Plus® Gum for thirty minutes in healthy volunteers. The 30 mg dosage showed excellent results and this data will be used to determine the optimal concentration in the IBS patient trial.

“These results show that excellent bioavailability for CBD may be achieved via our proprietary chewing gum delivery system, so that patients suffering from IBS may have symptomatic relief using an

... read more at: http://finance.yahoo.com/news/axim-biotech-receives-positive-pk-140000294.html

by